The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Salmon Calcitonin Use and Associated Cancer Risk
Abstract
Objective: To evaluate the strength of evidence supporting a possible association between salmon calcitonin (SCT) use and cancer incidence. Data Sources: Searches of MEDLINE/PubMed, MEDLINE/OVID, and EMBASE (January 1973 to September 2013) were performed using the key search terms salmon calcitonin, humans, nasal calcitonin, and (for EMBASE only) randomized controlled trial. We also performed a manual review of data reviewed by the US Food and Drug Administration (FDA) committee in 2013. Study Selection and Data Extraction: All articles identified from the data sources were evaluated and all information deemed relevant was included for this review. Data Synthesis: Intranasal and injectable SCT are FDA-approved for the treatment of postmenopausal osteoporosis. After a safety signal suggested a possible link between SCT use and prostate cancer, the European Medicines Agency and FDA regulatory agencies conducted analyses of SCT randomized controlled trial data to assess cancer-related adverse events and to readdress the approval status of SCT. Eighteen studies were found that compared nasal or oral SCT and placebo. In 15 of the 18 studies, the percentage of malignancy was greater in the SCT arm. The studies varied in quality, outcomes, and length. Most of the studies had poor-quality methods to assess new cancer cases. Conclusions: Current evidence may suggest an association between SCT use and cancer incidence based on studies with poor-quality cancer assessment methods. However, considering the lack of demonstrated efficacy of SCT to reduce fractures, clinicians should consider discontinuing its use for osteoporosis treatment regardless of the FDA’s final approval decision.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“2) The development of bisphosphonates and other effective drugs provide much better options for osteoporosis treatment (165).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [165]
In the citing paper
“sCT was first introduced to the market in 1974 and was subsequently approved by the United States Food and Drug Administra-tion for use in the treatment of postmenopausal osteoporosis, hypercalcemia, and Paget's disease (33,165).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [165]
In the citing paper
“At present, sCT use declined, and it is no longer considered an appropriate treatment option for osteoporosis for two main reasons: 1) a number of studies suggested an association between sCT use and cancer incidence (165).”
From The Activity of Peptides of the Calcitonin Family in Bone (2019) · cites this paper as [165]
In the citing paper
“A meta-analysis of 21 randomized, controlled clinical trials with calcitonin-salmon (nasal spray and investigational oral forms) suggests an increased risk of malignancies in calcitonin-salmon-treated patients compared to placebo-treated patients.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [80]
In the citing paper
“The overall incidence of malignancies reported in the 21 trials was higher among calcitonin-salmon-treated patients (4.1 %) compared with placebo-treated patients (2.9 %).”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [80]
Citations
Cites
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled Trials
LeLorier, J., Grégoire, G., Benhaddad, A., Lapierre, J., & Derderian, F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708213370806 · Cited by 1,171
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Randomized versus historical controls for clinical trials
Sacks, H., Chalmers, T. C., & Smith, H. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90815-4 · Cited by 834
Evidence for Calcitonin—A New Hormone from the Parathyroid That Lowers Blood Calcium
COPP, D. H., CAMERON, E. C., CHENEY, B. A., DAVIDSON, A. G. F., & HENZE, K. G. (1962) · Endocrinology · doi:10.1210/endo-70-5-638 · Cited by 697
IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis
Cranney, A., Guyatt, G., Griffith, L., Wells, G., Tugwell, P., Rosen, C., The Osteoporosis Methodology Group, & The Osteoporosis Research Advisory Group (2002) · Endocrine Reviews · doi:10.1210/er.2001-9002 · Cited by 604
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003376.pub3 · Cited by 499
Research works printed but not linked: 7
- Copp DH, 1994, Clin Invest Med, 17, 268
- Watts NB, 2004, J Manag Care Pharm, 10, 142
- 10.1002/(SICI)1097-0045(19970215)30:3<183::AID-PROS6>3.0.CO;2-N · doi:10.1002/(sici)1097-0045(19970215)30:3<183::aid-pros6>3.0.co;2-n
- Segawa N, 2001, Cancer Res, 61, 6060
- 10.1002/jbmr.1852 · DOI
- Wells GA, 2008, Cochrane Database Syst Rev, CD001155
- Wells G, 2008, Cochrane Database Syst Rev, CD004523
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
Long-term and sequential treatment for osteoporosis
Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00866-9 · Cited by 273
Bone Health and Osteoporosis Prevention and Treatment
MUÑOZ, M., ROBINSON, K., & Shibli-Rahhal, A. A. (2020) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000572 · Cited by 176
Metadata
- Authors
- Overman, R. A., Borse, M., & Gourlay, M. L.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2013-10-25
- Volume
- 47
- Issue
- 12
- Pages
- 1675-1684
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2105919535
- Semantic Scholar
- 2ec392b6ba56f518d4366439e809e9289a99c5fd
- Cited by
- 96
- References
- 42
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 6 · 2023: 1 · 2022: 8 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 3 · 2017: 12 · 2016: 14 · 2015: 13 · 2014: 8 · 2013: 1
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Annals of Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- salmon calcitonin, cancer risk, postmenopausal osteoporosis, intranasal calcitonin, prostate cancer, drug safety, randomized controlled trials, cancer incidence, FDA drug approval, fracture prevention
- MeSH terms
- Calcitonin, Humans, Neoplasms, Osteoporosis, Risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Salmon Calcitonin Use and Associated Cancer Risk. https://app.cochat.ai/papers/10.1177/1060028013509233
- The paper
- Overman, R. A., Borse, M., & Gourlay, M. L. (2013). Salmon Calcitonin Use and Associated Cancer Risk. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028013509233
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.